BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 23627575)

  • 1. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events.
    Chen SY; Wu N; Gulseth M; LaMori J; Bookhart BK; Boulanger L; Fields L; Schein J
    J Manag Care Pharm; 2013 May; 19(4):291-301. PubMed ID: 23627575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Warfarin Discontinuation in Patients With Unprovoked Venous Thromboembolism: A Large US Insurance Database Analysis.
    Xie L; Liu X; Phatak H; Mardekian J; Tan W; Baser O; Ramacciotti E
    Am J Ther; 2016; 23(6):e1744-e1753. PubMed ID: 26214203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
    Lin J; Lingohr-Smith M; Kwong WJ
    J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
    JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
    Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
    Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation.
    Spivey CA; Qiao Y; Liu X; Mardekian J; Parker RB; Phatak H; Claflin AB; Kachroo S; Abdulsattar Y; Chakrabarti A; Wang J
    J Manag Care Spec Pharm; 2015 Jul; 21(7):596-606. PubMed ID: 26108384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin.
    Nordstrom BL; Evans MA; Murphy BR; Nutescu EA; Schein JR; Bookhart BK
    Curr Med Res Opin; 2015 Mar; 31(3):439-47. PubMed ID: 25495136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.
    Casciano JP; Dotiwala ZJ; Martin BC; Kwong WJ
    J Manag Care Pharm; 2013 May; 19(4):302-16. PubMed ID: 23627576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trajectories of Oral Anticoagulation Adherence and Associated Clinical Outcomes During Long-Term Anticoagulation Among Medicare Beneficiaries With Venous Thromboembolism.
    Park H; Jones BL; Huang PL; Kang HR; Dietrich EA; DeRemer CE; Lo-Ciganic WH
    Ann Pharmacother; 2023 Dec; 57(12):1349-1360. PubMed ID: 36999519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism.
    Fang MC; Reynolds K; Fan D; Prasad PA; Sung SH; Portugal C; Garcia E; Go AS
    JAMA Netw Open; 2023 Aug; 6(8):e2328033. PubMed ID: 37581888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
    Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of parenteral anticoagulants and warfarin: impact on the risk of venous thromboembolism recurrence in the outpatient setting.
    Cai J; Preblick R; Zhang Q; Kwong WJ
    Am Health Drug Benefits; 2014 Nov; 7(8):444-51. PubMed ID: 25558306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
    Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
    J Thromb Thrombolysis; 2018 Oct; 46(3):339-345. PubMed ID: 29881958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Initiation Patterns, Modifications, and Medication Adherence Among Newly Diagnosed Heart Failure Patients: A Retrospective Claims Database Analysis.
    Deschaseaux C; McSharry M; Hudson E; Agrawal R; Turner SJ
    J Manag Care Spec Pharm; 2016 May; 22(5):561-71. PubMed ID: 27123917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and treatment patterns of patients with venous thromboembolism (VTE) transitioning from hospital to post-discharge settings.
    Burton T; Hlavacek P; Guo JD; Rosenblatt L; Mardekian J; Ferri M; Russ C; Kline JA
    Hosp Pract (1995); 2020 Oct; 48(4):196-205. PubMed ID: 32720816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of warfarin therapy among residents who developed venous thromboembolism in the nursing home.
    Reardon G; Pandya N; Nutescu EA; Lamori J; Damaraju CV; Schein J; Bookhart BK
    Am J Geriatr Pharmacother; 2012 Dec; 10(6):361-72. PubMed ID: 23217529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
    Simes J; Becattini C; Agnelli G; Eikelboom JW; Kirby AC; Mister R; Prandoni P; Brighton TA;
    Circulation; 2014 Sep; 130(13):1062-71. PubMed ID: 25156992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
    J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
    Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
    J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.